Showing 1881-1890 of 5771 results for "".
- Eyenovia Announces Topline Results From VISION-1 Phase 3 Study of MicroLine for the Treatment of Presbyopiahttps://modernod.com/news/eyenovia-announces-positive-topline-results-from-vision-1-phase-3-clinical-study-of-microline-for-the-treatment-of-presbyopia/2479241/Eyenovia announced that its VISION-1 study evaluating the company’s proprietary pilocarpine formulation, MicroLine, for the temporary improvement of near vision in adults with presbyopia, achieved its primary endpoint. Preparations are underway for a second phase 3 registration study, VISION-2. T
- SIFI and Bausch Health Russia Announce Strategic Commercial Partnershiphttps://modernod.com/news/sifi-and-bausch-health-russia-announce-strategic-commercial-partnership/2479213/Italian ophthalmic company SIFI announced it has entered into a strategic multi-year agreement with Bausch Health Russia to market its products treating ophthalmic disorders in Russia. Terms of the deal were not disclosed. Initial sales are expected in 2021, marketing 5 SIFI product
- Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22https://modernod.com/news/prevent-blindness-declares-second-annual-inherited-retinal-disease-ird-genetic-testing-week-as-may-16-22/2479209/Prevent Blindness has declared the second annual “Inherited Retinal Disease (IRD) Genetic Testing Week” as May 16-22, 2021. As part of this initiative, Prevent Blindness will be posting a series of educational graphics on its social media channels, including Facebook, Twitter, and Instagram.
- Arctic Vision Announces Exclusive Licensing Agreement With ActualEyeshttps://modernod.com/news/arctic-vision-announces-exclusive-licensing-agreement-with-actualeyes/2479210/Arctic Vision and ActualEyes, a clinical stage Japanese biotech company committed to the research and development of cell therapy for corneal endothelial diseases, jointly announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product cand
- ReGenTree Announces Additional Results From ARISE-3 Trial Using RGN-259 for the Treatment of Dry Eyehttps://modernod.com/news/regentree-announces-additional-results-from-arise-3-using-rgn-259-for-the-treatment-of-dry-eye/2479211/ReGenTree, a U.S. joint venture company between GtreeBNT and RegeneRx, announced results of additional analysis of the phase 3 clinical trial, ARISE-3, using RGN-259 for the treatment of dry eye syndrome. The company also pooled data from all three phase 3 clinical trials for dry eye. In A
- Johnson & Johnson Vision Announces FDA Approval of Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-announces-fda-approval-of-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2479199/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Abiliti-Overnight Therapeutic Lenses. This is the first and only FDA approved orthokeratology (ortho-k) contact lens for the management of myopia. “The FDA approval of Abiliti Overnight marks an
- Oculis Announces Positive Data From Two Proof-of-Concept Phase 2 Trials With OCS-02 in Dry Eye Disease and Acute Anterior Uveitishttps://modernod.com/news/oculis-announces-positive-data-from-two-proof-of-concept-phase-2-trials-with-ocs-02-in-dry-eye-disease-and-acute-anterior-uveitis/2479192/Oculis announced positive data from two clinical proof of concept phase 2 trials with OCS-02, its novel, topical anti-TNF alpha antibody fragment candidate, in dry eye disease (DED) and acute anterior uveitis (AAU). The data were presented for the first time at ARVO 2021, the annual meeting of th
- PharmAbcine Announces Nonclinical Data of PMC-403 for Vessel-Related Diseases at ARVOhttps://modernod.com/news/pharmabcine-announces-nonclinical-data-of-pmc-403-for-vessel-related-diseases-at-arvo/2479187/PharmAbcine announced that the company presented an e-poster featuring nonclinical data of PMC-403 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting on May 5th. PMC-403 is the company’s novel agonistic ant
- Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bankhttps://modernod.com/news/eyenovia-announces-new-25-million-credit-facility-with-silicon-valley-bank/2479182/Eyenovia announced that the company has entered into a new $25 million credit financing facility with Silicon Valley Bank (SVB). “This non-dilutive credit facility provides us with a significant amount of financial and operating flexibility at terms that we
- Clearside Biomedical Announces Multiple Poster Presentations at ARVOhttps://modernod.com/news/clearside-biomedical-announces-multiple-poster-presentations-at-arvo/2479185/Clearside Biomedical announced that multiple clinical poster presentations related to its suprachoroidal injection platform and programs were delivered at the Association for Research in Vision and Ophthalmology 2021 Virtual Meeting which took place May 1-7, 2021.